Given the increasing use of BRAF inhibitors as well as checkpoint blockade inhibitors to treat a number of cancers, we will discuss the clinical implications of the presence of BRAF V600E mutation and PD-L1 expression in RDD. The gene discussed is CD274; the disease is sinus histiocytosis with massive lymphadenopathy.